EGFR positive

P2, N=38, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Notably, SNA features achieved an AUC of 0.793, outperforming DLPS (0.596) and clinical variables (0.757). These findings suggest the value of integrating tissue-specific structural and semantic features for interpretable modeling of treatment response variability in HER2+BC.

Living in lower-income and lower-education areas and use of public or lack of insurance were associated with heterogeneous delays across subtypes and treatment modalities. This cross-sectional study of patients with dnMBC found racial and ethnic disparities in disease presentation and inequities in timely treatment for dnMBC across subtypes, emphasizing the need for tailored interventions to improve care delivery and outcomes.

P1/2, N=151, Recruiting, Takeda | Not yet recruiting --> Recruiting

P3, N=327, Enrolling by invitation, Avistone Biotechnology Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2030 | Trial primary completion date: Jan 2026 --> Jun 2028

Several of these candidates have entered early-phase clinical evaluation, marking a new era in CDK-targeted therapy. This review synthesizes recent preclinical and clinical advances, defines key challenges in optimizing efficacy and safety, and outlines future directions for integrating CDK-directed strategies within precision oncology frameworks.

Using panitumumab-IRDye800CW, we demonstrated heterogeneous accumulation in epidermal growth factor receptor-positive regions and quantified penetration gradients relative to tumor architecture. We established a multiplex imaging platform that enables single-cell analysis of therapeutic antibody delivery and pharmacodynamics in human formalin-fixed, paraffin-embedded tissues.

P=N/A, N=74, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital

When targeting the IC50, the prototype formulations required a monthly dose of 300 mg and a three-month dose of 1200 mg, both with intermediate-release profiles.The semimechanistic PBPK model successfully predicted the optimal dose and release profile. The results provided valuable insights for polymer grade selection and drug-to-polymer ratio optimisation.

Patients with HR+/HER2- ABC receiving palbociclib with higher comorbidity burden, especially blood and lymphatic system disorders, had poorer clinical outcomes. GHS/QoL was preserved regardless of comorbidity burden.

Luminal B was found to be the predominant molecular subtype. Molecular subtype had a significant association with grade and proliferation index.

HER2 expression is relatively low in this HNSCC cohort compared to other ADC targets, but there are 39.1% of cases with detectable HER2 exceeding historical estimates. Overall, ADC target levels in HNSCC for approved ADCs suggests that HNSCC patients may benefit from this class of drugs.